Bellerophon Presents New Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting

Stock Information for Bellerophon Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.